论文部分内容阅读
血小板糖蛋白ⅡbⅢ/a受体拮抗剂作用于血小板聚集的最后共同途径,有效抑制血小板聚集及血栓形成,明显改善心肌组织水平再灌注,提高急性心肌梗死患者直接经皮冠状动脉介入治疗术的成功率。拟对GPⅡbⅢ/a受体拮抗剂的作用机制及其在直接经皮冠状动脉介入治疗中的研究进展作一综述。
Platelet glycoprotein Ⅱ b Ⅲ / a receptor antagonist acts on the last common pathway of platelet aggregation, effectively inhibiting platelet aggregation and thrombosis, significantly improve myocardial tissue reperfusion and improve the success of direct percutaneous coronary intervention in patients with acute myocardial infarction rate. The mechanism of GPⅡbⅢ / a receptor antagonist and its research progress in direct percutaneous coronary intervention are reviewed.